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 ABSTRACT 
Background 
Esophageal impedance monitoring records changes in conductivity. During esophageal rest 
impedance baseline values may represent mucosal integrity. The aim of this study was to 
assess the influence of acid suppression on impedance baselines in a placebo controlled 
setting.  
Material and Methods 
Impedance recordings from 40 infants (0-6months) enrolled in randomized placebo controlled 
trials of proton pump inhibitor (PPI) were retrospectively analyzed. Infants underwent 24hr 
pH-impedance monitoring prior to and after two weeks of double blind therapy with placebo 
or a PPI. Typical clinical signs of gastroesophageal reflux (GER) were recorded and I-GERQ-R 
questionnaire was completed.  
Key results 
Median (IQR) impedance baseline increased on PPI treatment (from 1217 (826-1514) to 1903 
(1560-2194) Ohm, p<0.001) but not with placebo (from 1445 (1033-1791) to 1650 (1292-
1983) Ohm, p=0.13). Baselines before treatment inversely correlate with the number of GER, 
acid GER, weakly acid GER, acid exposure and symptoms. The change in baseline on treatment 
inversely correlates with acid exposure and acid GER. Patients with initial low baselines have 
no improved symptomatic response to treatment.  
Conclusions and Inferences  
Impedance baselines are influenced by GER and increase significantly more with PPI therapy 
than with placebo. Clinical impact of this observation remains undefined as targeting therapy 
at infants with low baselines does not improve symptomatic response to treatment. 







Proton pump inhibitors 
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 INTRODUCTION 
Esophageal multichannel intraluminal impedance is used for the detection of 
gastroesophageal reflux (GER) episodes in infants, children and adults  (1-3). This is a 
technique to measure esophageal flow represented by changes in conductivity of adjacent 
contents between multiple electrode pairs on a catheter (4). Impedance values, representing 
changes in conductivity, drop in the presence of highly conductive contents, such as saliva or 
gastric fluids indicating a liquid swallow or GER. Less conductive bolus es, such as air, cause an 
increase in impedance signal. When the esophagus is at rest, the impedance signal, referred 
to as the impedance baseline, is likely to reflect the conductivity of the esophageal mucosa (5-
8). Low baselines have been observed in patients with esophagitis  (6), NERD patients, patients 
with pathological acid exposure (7) and in patients with impaired esophageal motility (9). 
Farré et al have demonstrated that impedance is a useful tool for the evaluation of mucosal 
integrity and that patients with GER disease (GERD) and non-erosive reflux disease (NERD) 
have lower baselines compared to healthy volunteers  (10). The authors report that the 
changes in baseline are not only related to macroscopic changes and secretion of 
inflammatory fluids, as seen in esophagitis, but to more subtle changes in the esophageal 
mucosa such as dilated intracellular spaces (DIS). DIS have been postulated to be the 
mechanism underlying NERD, providing a pathophysiological explanation for increased acid 
perception (11, 12). A significant correlation has been observed between the sensation of pain 
after acid infusion and baseline values suggesting a relationship linking baselines, DIS and 
perception of pain (10).  
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In infants and children proton pump inhibitors (PPIs) are the most commonly used therapeutic 
agents for the treatment of GERD. PPI therapy is proven effective for healing esophagitis in 
adults (13-15), for reducing acid exposure in infants (16-18) and is suggested to heal erosive 
esophagitis in 89% of children (19). However PPIs have not been proven to relieve symptoms 
of GERD in infants (20-22). The diagnosis and treatment of infantile GERD remains 
controversial with no evidence supporting empirical PPI therapy for treating GER clinical signs, 
such as irritability, vomiting and feed refusal (21, 23).  
With endoscopy being difficult to perform in infants, impedance baselines may potentially be 
a marker of changes to mucosal integrity likely in increase symptom perception and therefore 
supportive of a diagnosis of GERD and a justification for PPI therapy. We have recently 
reported an increase in impedance baseline values in infants on PPI therapy in an open label, 
non placebo controlled trial (5). These data suggest that PPIs may change mucosal integrity 
through suppression of gastric acid and restoration of DIS. This effect was most prominent in 
those with initial low baselines. These findings are however uncontrolled, therefore we 
reanalyzed impedance recordings from infants  with clinical signs of GERD, enrolled in 
randomized placebo controlled trials of PPI. We hypothesize that PPI treatment increases 
impedance baselines whereas placebo does not and that patients with lower baselines have 
more GER clinical signs and benefit more from therapy.   
 
MATERIAL AND METHODS  
 
Patients 
Patient data from a research database compiled of data from previously conducted 
randomized controlled trials (RCT) of anti-reflux therapies were reanalyzed. RCT protocols 
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were approved by the Human Research Ethics and Drug Therapeutics Committee of the 
Women’s and Children’s Hospital, Adelaide, Australia.  
 
Protocol 
Preterm and term infants from zero to six months of age were enrolled. Infants were included 
if they presented with clinical signs suggestive of GER such as irritability, crying, excessive 
vomiting, regurgitation, coughing, feed refusal, unsettled behavior, back arching, failure to 
thrive or apneas and had failed to respond to non-pharmacological therapy. Patients 
underwent eight hour pH-impedance monitoring and clinical signs were continuously 
recorded by trained staff. Episodes of vomiting, regurgitation, irritability, crying, fussing, 
cough, sneeze, backarching, choking, gagging were scored during the study. Primary 
caretakers completed a validated infant questionnaire, the I-GERQ-R (24). After the eight hour 
hospital based study, the pH-impedance probe was left in place for 24 hr GER assessment 
either in hospital or at home.  
GER and impedance baseline values were recorded using a single use infant pH-impedance 
catheter with seven sensors (six impedance channels) spaced 1.5 cm apart (ComforTec MII/pH 
probe, Sandhill Scientific, Highlands Ranch, CO, USA). The pH sensor was placed at the third 
vertebrae above the diaphragm as confirmed by a thoracic X-ray.  
After the initial study patients were randomized (double blind) and received two weeks of PPI 
(omeprazole 1 mg kg-1 day-1 once daily; esomeprazole 0.5 mg kg-1 day-1 once daily) or placebo 
which consisted of bicarbonate solution (vehicle used in PPI preparations). For the purpose of 
this study the groups receiving omeprazole and esomeprazole are combined into one ‘PPI 
group’. Eight hour pH-impedance, manual symptoms scoring, I-GERQ-R and 24hr pH-
impedance monitoring was repeated on therapy after two weeks.  
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 Data analysis 
Impedance analysis 
The eight hour and 24hr pH-impedance tracings (Bioview; Sandhill Scientific) were analyzed by 
two observers for the presence of liquid and mixed bolus GER. Distal esophageal acid 
exposure time, reflux index (RI) was calculated as the % time pH<4. I-GERQ-R scores were 
calculated as previously described (24).  
 
Baseline calculation by automated analysis  
Raw impedance values for all catheter channels were exported from each recording in text 
format at one sample per second. The baseline value per channel was estimated for both the 
initial 8h symptom assessment period and the full 24h study period using automated analysis 
procedures performed on the raw impedance data using a Matlab™ based algorithm.  The 
algorithm was designed to filter the data, by removing the influence of rapid impedance dips 
and rises typically associated with reflux episodes and swallowing.  
The algorithm operated as follows:  
Firstly all data samples >5000 Ohm (representing gas reflux) were excluded. We assumed that 
the majority of liquid reflux related impedance drops to be excluded would have durations of 
<10sec. Each 10min period of tracing was therefore divided into separate 10sec intervals and 
the lowest level impedance was determined for each interval (Figure 1A). Of the sixty 
impedance values sampled, those above and below one standard deviation of the mean were 
removed (Figure 1B) and the mean of the residual samples was used to estimate of baseline 
impedance for each separate 10min period (Figure 1B). This estimation of baseline impedance 
Archived at the Flinders Academic Commons: http://dspace.flinders.edu.au/dspace/ 
was then performed for all consecutive 10min periods of the tracing and then the median of 
all periods was used to estimate impedance baseline for the entire study (Figure 1C).  
The values derived via this automated analysis method have been separately validated against 
a more time consuming manual analysis method. In this validation baseline estimates for ten 
studies showed an excellent agreement (ICC 0.988, p<0.001) (person communication R van 
der Pol, Academic Medical Centre, Amsterdam). 
 
Symptom analysis 
For clinical signs analysis we calculated the sum of all clinical signs recorded by trained staff 
continuously monitoring infants during the eight hour study. Vomiting, crying and coughing 
episodes were assessed separately as well, as these were consistently observed in all infants. 
GER symptom association probability (SAP) was calculated for all clinical signs together and 
for vomiting, crying and coughing separately. The SAP is based on the Fisher’s exact test 
calculating the probability that GER and the clinical signs are unrelated. The SAP is calculated 
as (1 – p) x 100% and a SAP of >95% is referred to as a positive SAP (1).  
 
Statistical analysis 
We report on the influence of therapy on baselines based on the 24 hour pH-impedance 
recordings. The data on correlation between baselines, GER, acid exposure and clinical signs 
are based on the eight hour pH-impedance study as clinical signs were only continuously and 
reliably monitored during this period.  
The baseline data were not normally distributed and are shown as medians (interquartile 
range). Comparisons were made using Wilcoxon’s  signed rank test and Spearman’s correlation 
statistics. Spearman partial correlations were performed to assess the influence of different 
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variables. A Spearman’s r of 0 - 0.3 was considered a weak correlation, 0.3 - 0.6 a moderate 




Data were derived from 40 preterm and term infants, 18 (45%) male between the age of zero 
and six months, mean age was 7 weeks (IQR 3-12 weeks). Eleven infants received treatment 
with esomeprazole, 16 infants received omeprazole and 13 infants received placebo.  
Bolus GER parameters such as total number of GER episodes, acid GER, weakly acid GER, 
reflux index (RI) and number of clinical signs scored during eight hour monitoring for the 
different treatment groups are presented in Table 1.  
 
Impedance baseline values in the esophagus 
Median (IQR) impedance baseline values measured in the initial study at the six impedance 
segments on the catheter ranged from 1383 (1070-1794) Ohm in the most distal channel to 
1125 (912-1856) Ohm in the most proximal channel, the third most distal segment showed 
the highest impedance baseline 1956 (1474-2295) Ohm. Baseline values of the entire 
esophagus measured over 24hrs (1436 (1196-1627) Ohm) are comparable to the values 
measured in the eight hour study (1454 (1209-1776) Ohm). The most prominent changes in 
impedance baselines occurred in the most distal, most exposed, impedance segment. 
Throughout the manuscript we report the baseline values in the most distal impedance 
segment if not indicated otherwise.   
 
Impact of treatment on impedance baseline 
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The median (IQR) 24hr impedance baseline increased significantly following PPI treatment 
(from 1217 (826-1514) to 1903 (1560-2194) Ohm after therapy, p<0.001) but not with placebo 
(from 1445 (1033-1791) to 1650 (1292-1983) Ohm after therapy, p=0.13). The change in 
baseline in the placebo and PPI group is shown in Figure 2. The change in baseline at different 
measuring points in the esophagus is presented in Table 2.  
 
Impedance baselines in relation to other parameters  
Before therapeutic intervention, impedance baselines are inversely correlated to the number 
of GER episodes, acid GER episodes, weakly acid GER episodes, reflux index, GER related 
clinical signs and vomiting episodes (Table 3). I-GERQ-R outcomes, number of cough episodes 
and number of crying episodes did not correlate to baseline values at any time.  
 
The difference in impedance baseline during therapy showed an inverse correlation to the 
difference in reflux index and the number of acid GER episodes across all groups (Spearman r 
= -0.41 (moderate), p=0.009 and Spearman r = -0.38 (moderate), p=0.015 respectively). 
Subdividing groups based on treatment did not reveal other correlations.  
 
Outcome for different initial baselines 
Although we observed an inverse correlation between impedance baselines and the numbers 
of clinical signs, we did not observe a different response to treatment in patients with low 
baselines in terms of the total number of clinical signs recorded, crying, vomiting or coughing 
episodes. We used cut off values for low baselines of <1000, <1250, <1500, <1750 and <2000 
Ohms. Including only patients with a positive GER – symptom association based on a positive 
SAP before treatment did not change these results.  
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 DISCUSSION 
 
In this study we assessed the influence of acid suppression therapies on impedance baseline 
values and the relation between impedance baseline and clinical signs in patients enrolled in 
RCTs performed in our centre. We demonstrate that PPI treatment significantly increases 
impedance baseline, whereas  treatment with placebo does not. Lower impedance baselines 
pre treatment correlate with higher total number of GER episodes, number of acid GER 
episodes, number of weakly acid GER episodes, reflux index and number of GER related 
clinical signs. The increase in impedance baselines on therapy correlates with the reduction in 
acid exposure as well as number of acid GER. These findings suggest that impedance baseline 
values may reflect integrity of the esophageal mucosa which appears to be driven by the 
balance between damage caused by bolus GER, acid exposure(7) and possibly other factors 
(12, 25, 26) and protection by the tight squamous epithelium of the esophageal mucosa.  
 
In our population we have established that impedance values throughout the esophagus are 
rather consistent, with the exception of the channel nearest to the heart and aortic arch. In 
that channel the narrowing of the esophagus most likely explains the rise in impedance 
baseline measured. Largest differences with therapy were seen in the most distal segment 
which is also the segment most exposed to gastric refluxate. This has also been observed by 
others  (7, 10),  
 
Although correlations do not prove causality, it is interesting that we observed an inverse 
correlation between impedance baselines and total numbers of GER, both weakly acidic and 
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acidic, acid exposure, and GER related clinical signs before treatment. It has been shown that 
acid and weakly acid solutions can cause DIS in adults (10, 12). Furthermore, DIS can present 
in adult patients with NERD (27-29). Moreover, increased DIS has been associated with 
increased perception of heartburn in NERD patients (12). It can be argued that infants are 
similar to adults with NERD in terms of GER like clinical signs without erosive esophagitis. 
Barlow has postulated a unifying hypothesis for the pathogenesis of heartburn in patients 
with NERD(11); the presence of low tissue resistance enables the diffusion of H+ ions into the 
intercellular space, activating chemosensitive nociceptors whose signals are transmitted to 
the brain and perceived as heartburn. This hypothesis could explain the correlation we 
observed between more acid GER and lower baselines  and between lower baselines and 
increased number of clinical signs.  
 
The role of weakly acidic GER has not been addressed in this hypothesis. It has been shown 
that infusions with weakly acid solutions cause similar DIS to acid solutions (12). This is not 
supported by our findings that patients on PPI treatment, who have more weakly acid GER 
have higher impedance baselines. The exact relation between weakly acid solutions, weakly 
acid GER, DIS and baseline levels remains to be established.  
 
Anti reflux treatment in infants has been controversial, largely due to the fact that no 
treatment has been proven effective for reducing clinical signs of GER (21). Based on the 
observation that low baselines correlate to acid induced heartburn in adults  we hypothesized 
that patients with low baselines before treatment would benefit more from treatment. 
However we did not observe a change in clinical signs on treatment in any of the groups, 
neither did we observe a correlation in change in baseline and change in clinical signs. Only a 
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few patients had low baselines and therefore this negative finding may be due to insufficient 
statistical power. It should be noted however that an increasing number of placebo controlled 
trials have failed to demonstrate symptomatic improvement with PPI. Hence the most likely 
conclusion is that the clinical signs suggestive of GER such as crying, irritability and coughing 
are very non-specific to GERD in infants.  
 
A limitation of this study is that endoscopic data are unavailable to correlate the change in 
baseline to esophageal macroscopic mucosal findings and histology. This data is difficult to 
acquire because endoscopy is infrequently performed in infants and only performed in those 
who have severe complications and are therapy resistant. However, based on Farré et al’s 
(REF) recent observations that clearly link impaired esophageal mucosal integrity to 
impedance baseline measurements (10), this study suggests that PPI’s may improve mucosal 
integrity compared to placebo.  
 
Although a relationship between symptom severity and baselines was not identified, these 
results are nevertheless of clinical relevance. Future research should assess if impedance is 
able to detect patients at risk for esophagitis. Impedance measurements are easier and safer 
to perform in infants than endoscopy and therefore has great potential in this patient 
population. Furthermore a better tool to identify patients who will respond to treatment is 
much awaited. Whilst symptomatic changes do not appear to correlate with changes in 
impedance baselines in the patient cohort studied, this approach may still have potential and 
is worthy of further investigation in older patients who may benefit by repeat investigations to 
evaluate mucosal healing (????). 
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In conclusion, we have demonstrated that PPI therapy increases esophageal baseline levels 
suggesting that PPI’s improve esophageal mucosal integrity whereas placebo does not have 
this effect. Infants with low baselines before therapy do not have a better response to 
treatment in terms of numbers of clinical signs compared to infants with high initial baselines, 
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Table 1. GER parameters pre and post treatment  
GER parameters per treatment group. Reflux index in % acid exposure during the study. 
Clinical signs are the total number of clinical signs recorded during the eight hour study.  
  Placebo N=13        Antacid N=13     
  Pre treatment On treatment 
p-
value    Pre treatment On treatment p-value 
GER total 76 (60-102) 70 (56-101) 0.81  GER total 49 (29-68) 31 (22-41) 0.023 
GER acid 30 (12-48) 22 (11-28) 0.39  GER acid 15 (4-26) 6 (2-22) 0.05 
GER WA 45 (33-67) 55 (33-72) 0.44  GER WA 27 (21-44) 20 (15-29) 0.093 
Reflux index 31 (15-59) 26 (20-40) 0.6  Reflux index 1.2 (0.7-12.3) 4.6 (0.1-10.7) 0.05 
Clinical signs 146 (135-201) 166 (131-209) 0.25  Clinical signs 131 (83-208) 138 (105-220) 0.2 
         
  Omeprazole N=16      Esomeprazole N=11   
  Pre treatment On treatment p-value    Pre treatment On treatment p-value 
GER total 46 (36-58) 30 (22-43) <0.001  GER total 131 (78-215) 89 (51-152) 0.041 
GER acid 17 (8-26) 2 (0-8) 0.001  GER acid 39 (17-91) 5 (2-11) 0.003 
GER WA 32 (23-46) 25 (18-37) 0.133  GER WA 87 (40-130) 78 (46-134) 0.213 
Reflux index 14.8 (3.7-23.1) 1.4 (0.1-4.3) 0.008  Reflux index 46.9 (30.4-55.9) 10.2 (0.2-34.0) 0.006 
Clinical signs 105 (70-158) 119 (90-151) 0.88  Clinical signs 171 (145-191) 140 (123-186) 0.25 
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 Table 2. Baseline values per 24 hr study pre and post treatment  
 Baseline Pre Baseline Post p-value 
Placebo  N=13 1445 (1033-1791) 1650 (1292-1983) 0.13 
Antacid N=13 1619 (860-2215) 1546 (869-2408) 0.237 
Omeprazole N=16 1167 (856-1579) 1976 (1649-2067) 0.005 
Esomeprazole N=11 1291 (666-1493) 1903 (1254-2239) 0.006 
 
Table 2 Baseline values per 24 hr study pre and post treatment for the most distal channel. 







Table 3 Correlation between GER parameters and impedance baselines 
 Correlation Spearman’s r p-value 
GER total strong -0,61 <0.001 
GER acid strong -0,66 <0.001 
GER weakly acid moderate -0,38 0.005 
Reflux index strong -0,63 <0.001 
Symptom total moderate -0,38 0.005 




Vomiting moderate -0.53 <0.001 
Table 3. Correlation between GER parameters and impedance baselines before therapeutic 
intervention based on the eight hour study. 
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 Figures legends 
 
Figure 1. Automated calculation of impedance baseline values.  
A. One minute time interval. The circles in the figure represent the 6 minimum impedance 
data points per minute used for the calculations.  
B. Ten minute time interval to calculated mean and standard deviation 60 samples (obtained 
from panel A). Samples above and below 1 standard deviation of the mean were removed 
(open circles). The mean of the remaining samples (closed circles) was calculated and this 
number was taken as the estimate of baseline impedance for each 10min interval.  
C. Eight hour time interval. The analysis (panel B) was repeated for consecutive 10min 
intervals of the complete dataset and the median of all 10min intervals was used to estimate 
the overall impedance baseline value.  
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Figure 2. Difference in baseline post – pre treatment per treatment group 
Difference in baseline value on treatment – pre treatment per treatment group. Baselines in 
the omeprazole and esomeprazole group are significantly increased compared to placebo. The 
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